|
LBR expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.86040000071941E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.85680000053657E-08 |
| Normal-vs-Stage2 |
9.03849994848827E-10 |
| Normal-vs-Stage3 |
4.90229999927649E-08 |
| Normal-vs-Stage4 |
1.39269999976932E-08 |
| Stage1-vs-Stage2 |
1.138150E-02 |
| Stage1-vs-Stage3 |
6.176600E-01 |
| Stage1-vs-Stage4 |
1.744000E-01 |
| Stage2-vs-Stage3 |
8.791600E-02 |
| Stage2-vs-Stage4 |
5.547600E-01 |
| Stage3-vs-Stage4 |
4.013600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.99770000226019E-08 |
| Normal-vs-AfricanAmerican |
2.24719998165313E-09 |
| Normal-vs-Asian |
1.16880000122777E-08 |
| Caucasian-vs-AfricanAmerican |
2.335800E-02 |
| Caucasian-vs-Asian |
1.517410E-01 |
| AfricanAmerican-vs-Asian |
4.278600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.10219999688499E-08 |
| Normal-vs-Female |
1.94999999481027E-08 |
| Male-vs-Female |
9.331800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.43770000016197E-07 |
| Normal-vs-Age(41-60Yrs) |
4.15559997524184E-09 |
| Normal-vs-Age(61-80Yrs) |
2.31140000472863E-08 |
| Normal-vs-Age(81-100Yrs) |
1.082780E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.086000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.301400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.110400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.545600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.361200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.342630E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.989800E-01 |
| Classical-VS-Follicular |
2.13919999999534E-05 |
| Classical-VS-Other |
1.960600E-01 |
| Classical-VS-Normal |
2.4332000003735E-07 |
| Tall-VS-Follicular |
3.932300E-02 |
| Tall-VS-Other |
3.728200E-01 |
| Tall-VS-Normal |
3.74140000003464E-06 |
| Follicular-VS-Other |
9.030800E-01 |
| Follicular-VS-Normal |
2.32480035222693E-10 |
| Other-VS-Normal |
6.31519999999552E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.19570003792791E-09 |
| Normal-vs-N1 |
2.94650004395436E-09 |
| N0-vs-N1 |
7.264800E-01 |
|
|
